Advanced

Does immune-tolerance treatment with Alum-formulated GAD65 protect insulin-production in the pancreatic islet β cells?

Elding Larsson, Helena LU and Lernmark, Åke LU (2011) In Human Vaccines 7(1). p.45-49
Abstract
Type 1 diabetes is a serious chronic disease in which the pancreatic islet beta cells are destroyed by autoimmunity specifically directed to intracellular autoantigens. Still undefined environmental factors are likely to initiate the disease process. One of the autoantigens is glutamic acid decarboxylase (GAD65) and attempts are made to induce immunological tolerance against this autoantigen. Alum-formulated GAD65 (Diamyd (®)) has been given subcutaneously in two injections with one month apart to recent onset type 1 diabetes patients with positive GAD65 autoantibodies. The injections were found to preserve residual β-cell function without treatment related serious adverse events. Phase III studies in children with recent onset type 1... (More)
Type 1 diabetes is a serious chronic disease in which the pancreatic islet beta cells are destroyed by autoimmunity specifically directed to intracellular autoantigens. Still undefined environmental factors are likely to initiate the disease process. One of the autoantigens is glutamic acid decarboxylase (GAD65) and attempts are made to induce immunological tolerance against this autoantigen. Alum-formulated GAD65 (Diamyd (®)) has been given subcutaneously in two injections with one month apart to recent onset type 1 diabetes patients with positive GAD65 autoantibodies. The injections were found to preserve residual β-cell function without treatment related serious adverse events. Phase III studies in children with recent onset type 1 diabetes are ongoing along with a study (DIAPREV-IT) aimed at testing whether Diamyd (®) may prevent the clinical onset of diabetes in non-diabetic children with GAD65 autoantibodies and at least one more islet autoantibody. Future studies may include investigation of Diamyd (®) in combination with other immunomodulating autoantigens. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adjuvants, Immunologic, Alum Compounds, Autoimmune diseases, Clinical Trial, Phase III as Topic, Diabetes Mellitus, Type 1, Glutamate Decarboxylase, Humans, Immune Tolerance, Immunization, Secondary, Injections, Subcutaneous, Vaccination, Journal Article, Review
in
Human Vaccines
volume
7
issue
1
pages
5 pages
publisher
Landes Bioscience
external identifiers
  • wos:000288989300013
  • scopus:79551714647
ISSN
1554-8600
DOI
10.4161/hv.7.1.14488
language
English
LU publication?
yes
id
4d404a22-5b23-450f-85dc-dd71b2b0c2f9 (old id 1925366)
date added to LUP
2011-05-02 09:36:42
date last changed
2017-09-07 14:31:30
@article{4d404a22-5b23-450f-85dc-dd71b2b0c2f9,
  abstract     = {Type 1 diabetes is a serious chronic disease in which the pancreatic islet beta cells are destroyed by autoimmunity specifically directed to intracellular autoantigens. Still undefined environmental factors are likely to initiate the disease process. One of the autoantigens is glutamic acid decarboxylase (GAD65) and attempts are made to induce immunological tolerance against this autoantigen. Alum-formulated GAD65 (Diamyd (®)) has been given subcutaneously in two injections with one month apart to recent onset type 1 diabetes patients with positive GAD65 autoantibodies. The injections were found to preserve residual β-cell function without treatment related serious adverse events. Phase III studies in children with recent onset type 1 diabetes are ongoing along with a study (DIAPREV-IT) aimed at testing whether Diamyd (®) may prevent the clinical onset of diabetes in non-diabetic children with GAD65 autoantibodies and at least one more islet autoantibody. Future studies may include investigation of Diamyd (®) in combination with other immunomodulating autoantigens.},
  author       = {Elding Larsson, Helena and Lernmark, Åke},
  issn         = {1554-8600},
  keyword      = {Adjuvants, Immunologic,Alum Compounds,Autoimmune diseases,Clinical Trial, Phase III as Topic,Diabetes Mellitus, Type 1,Glutamate Decarboxylase,Humans,Immune Tolerance,Immunization, Secondary,Injections, Subcutaneous,Vaccination,Journal Article,Review},
  language     = {eng},
  month        = {01},
  number       = {1},
  pages        = {45--49},
  publisher    = {Landes Bioscience},
  series       = {Human Vaccines},
  title        = {Does immune-tolerance treatment with Alum-formulated GAD65 protect insulin-production in the pancreatic islet β cells?},
  url          = {http://dx.doi.org/10.4161/hv.7.1.14488},
  volume       = {7},
  year         = {2011},
}